Document is current
Any future updates will be listed below
-
Authors
Zhang, Junbing https://orcid.org/0000-0001-7746-1145
Ali, Md Yousuf
Chong, Harrison Byron
Tien, Pei-Chieh https://orcid.org/0000-0002-0012-0155
Woods, James
Noble, Carolina https://orcid.org/0000-0002-9527-536X
Vornbäumen, Tristan
Ordulu, Zehra https://orcid.org/0000-0002-3218-1075
Possemato, Anthony P.
Harry, Stefan
Fonticella, Jay Miguel
Fellah, Lina
Harrison, Drew https://orcid.org/0009-0009-5232-0640
Ge, Maolin https://orcid.org/0000-0002-8803-1463
Khandelwal, Neha https://orcid.org/0000-0001-7831-6820
Huang, Yingfei
Chauvin, Maëva https://orcid.org/0000-0003-0129-5480
Bischof, Anica Tamara
Hambelton, Grace Marie https://orcid.org/0000-0002-0893-6773
Gohar, Magdy Farag
Zhang, Siwen
Choi, MinGyu
Bouberhan, Sara
Oliva, Esther
Mino-Kenudson, Mari
Pavlova, Natalya N.
Lawrence, Michael
Gainor, Justin F. https://orcid.org/0000-0001-8697-4081
Beausoleil, Sean A. https://orcid.org/0000-0002-3356-4641
Bardeesy, Nabeel https://orcid.org/0000-0003-3867-0416
Mostoslavsky, Raul https://orcid.org/0000-0002-7740-5212
Pépin, David https://orcid.org/0000-0003-2046-6708
Ott, Christopher J. https://orcid.org/0000-0001-6142-7241
Liau, Brian https://orcid.org/0000-0002-2985-462X
Bar-Peled, Liron https://orcid.org/0000-0003-2687-9546
- License Information
-
More Information
Article History
Received: 4 June 2024
Accepted: 7 February 2025
First Online: 26 March 2025
Competing interests
: L.B.-P. is a founder, consultant and holds privately held equity in Scorpion Therapeutics. A.P.P. and S.A.B. are employees of Cell Signaling Technology. B.L. is a founder, member of the scientific advisory board, and equity holder in Light Horse Therapeutics. M.M.-K. has served as a compensated consultant for AstraZeneca, Roche, BMS, Innate, Boehringer-Ingelheim, Sanofi, Daiichi-Sankyo and AbbVie and has received royalties from Elsevier. J.F.G. has served as a compensated consultant for Amgen, AstraZeneca, Mariana Therapeutics, Mirati Therapeutics, Merus Pharmaceuticals, Nuvalent, Pfizer, Novocure, AI Proteins, Novartis, Silverback Therapeutics, Sanofi, Blueprint Medicines, Bristol Myers Squibb, Genentech, Gilead Sciences, ITeos Therapeutics, Jounce Therapeutics, Karyopharm Therapeutics, Lilly/Loxo, Merck, Moderna Therapeutics and Takeda; has received honorarium from Novartis, Merck, Novartis, Pfizer, Takeda; has received institutional research funding from Adaptimmune, Alexo Therapeutics, AstraZeneca, Blueprint Medicines, Bristol Myers Squibb, Genentech, Jounce Therapeutics, Merck, Moderna Therapeutics, Novartis, NextPoint Therapeutics and Palleon Pharmaceuticals; has recreived research support from Novartis, Genentech and Takeda; has equity in AI Proteins; and has an immediate family member who has equity in and is employed by Ironwood Pharmaceuticals. All other authors declare no competing interests.
